Tianjin, March 1, 2023 – CanSino Biologics Inc. (“CanSinoBIO” or “the Company”) (SSE: 688185, HKEX: 06185) today announced that the Badan Pengawas Obat dan Makanan (“BPOM”) has granted the Company Emergency Use Approval for its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation Convidecia Air® as a heterologous booster.

The latest research[1] published by Preprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet supports the safety and efficacy profile of Convidecia Air®. Clinical data showed that boosting with Convidecia Air® for people primed with three doses of inactivated vaccine, the neutralizing antibody level against the Omicron BA.5 at Day 28 was 6 times of the level observed in the homologous inactivated booster group.

In March 2022, CanSinoBIO received the BPOM’s approval for its intramuscular COVID-19 vaccine Convidecia®. Based on the same adenovirus-vectored technological platform as the intramuscular version, Convidecia Air® shows advantages in large-scale vaccination programs as each dose requires only one-fifth dosage of the injectable vaccine, and is a needle-free, painless, and non-invasive option. Utilizing Aerogen’s proprietary aerosol drug delivery technology, Convidecia® is administered via a nebulizer, atomizing the liquid vaccine into tiny particles that can be inhaled through the mouth and enter the human respiratory tract and lungs to induce a mucosal immune response, in addition to the humoral and cellular immunity induced by traditional COVID-19 vaccines.

Convidecia Air® is one of the CanSinoBIO’s latest technological innovations and has been included in the national heterologous booster programs in China and Morocco. The Company recently published phase IIb trial results for its mRNA COVID-19 vaccine and is currently preparing for phase III clinical research.

[1] Source: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4308756